mTORC1 and JNK coordinate phosphorylation of the p70S6K1 autoinhibitory domain in skeletal muscle following functional overloading

Am J Physiol Endocrinol Metab. 2014 Jun 15;306(12):E1397-405. doi: 10.1152/ajpendo.00064.2014. Epub 2014 May 6.

Abstract

The present project was designed to investigate phosphorylation of p70S6K1 in an animal model of skeletal muscle overload. Within 24 h of male Sprague-Dawley rats undergoing unilateral tenotomy to induce functional overloading of the plantaris muscle, phosphorylation of the Thr³⁸⁹ and Thr⁴²¹/Ser⁴²⁴ sites on p70S6K1 was significantly elevated. Since the Thr⁴²¹/Ser⁴²⁴ sites are purportedly mammalian target of rapamycin complex 1 (mTORC1) independent, we sought to identify the kinase(s) responsible for their phosphorylation. Initially, we used IGF-I treatment of serum-deprived HEK-293E cells as an in vitro model system, because IGF-I promotes phosphorylation of p70S6K1 on both the Thr³⁸⁹ and Thr⁴²¹/Ser⁴²⁴ sites in skeletal muscle and in cells in culture. We found that, whereas the mTOR inhibitor TORIN2 prevented the IGF-I-induced phosphorylation of the Thr⁴²¹/Ser⁴²⁴ sites, it surprisingly enhanced phosphorylation of these sites during serum deprivation. JNK inhibition with SP600125 attenuated phosphorylation of the Thr⁴²¹/Ser⁴²⁴ sites, and in combination with TORIN2 both the effect of IGF-I and the enhanced Thr⁴²¹/Ser⁴²⁴ phosphorylation during serum deprivation were ablated. In contrast, both JNK activation with anisomycin and knockdown of the mTORC2 subunit rictor specifically stimulated phosphorylation of the Thr⁴²¹/Ser⁴²⁴ sites, suggesting that mTORC2 represses JNK-mediated phosphorylation of these sites. The role of JNK in mediating p70S6K1 phosphorylation was confirmed in the animal model noted above, where rats treated with SP600125 exhibited attenuated Thr⁴²¹/Ser⁴²⁴ phosphorylation. Overall, the results provide evidence that the mTORC1 and JNK signaling pathways coordinate the site-specific phosphorylation of p70S6K1. They also identify a novel role for mTORC1 and mTORC2 in the inhibition of JNK.

Keywords: MAPK signaling; muscle hypertrophy; tenotomy.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Carrier Proteins / antagonists & inhibitors
  • Carrier Proteins / genetics
  • Carrier Proteins / metabolism
  • Cumulative Trauma Disorders / metabolism*
  • Cumulative Trauma Disorders / physiopathology
  • Disease Models, Animal*
  • HEK293 Cells
  • Humans
  • Insulin-Like Growth Factor I / metabolism
  • MAP Kinase Signaling System* / drug effects
  • Male
  • Mechanistic Target of Rapamycin Complex 1
  • Mechanistic Target of Rapamycin Complex 2
  • Mitogen-Activated Protein Kinase 8 / antagonists & inhibitors
  • Mitogen-Activated Protein Kinase 8 / metabolism*
  • Multiprotein Complexes / antagonists & inhibitors
  • Multiprotein Complexes / genetics
  • Multiprotein Complexes / metabolism*
  • Muscle, Skeletal / drug effects
  • Muscle, Skeletal / metabolism*
  • Muscle, Skeletal / physiopathology
  • Phosphorylation / drug effects
  • Protein Interaction Domains and Motifs
  • Protein Kinase Inhibitors / pharmacology
  • Protein Processing, Post-Translational / drug effects
  • Rapamycin-Insensitive Companion of mTOR Protein
  • Rats
  • Rats, Sprague-Dawley
  • Ribosomal Protein S6 Kinases / chemistry
  • Ribosomal Protein S6 Kinases / metabolism*
  • Serine / metabolism
  • TOR Serine-Threonine Kinases / antagonists & inhibitors
  • TOR Serine-Threonine Kinases / genetics
  • TOR Serine-Threonine Kinases / metabolism*
  • Threonine / metabolism

Substances

  • Carrier Proteins
  • Multiprotein Complexes
  • Protein Kinase Inhibitors
  • Rapamycin-Insensitive Companion of mTOR Protein
  • rictor protein, rat
  • Threonine
  • Serine
  • Insulin-Like Growth Factor I
  • Mechanistic Target of Rapamycin Complex 1
  • Mechanistic Target of Rapamycin Complex 2
  • Ribosomal Protein S6 Kinases
  • Rps6kb1 protein, rat
  • TOR Serine-Threonine Kinases
  • Mitogen-Activated Protein Kinase 8